Survodutide Research Guide

Full name: Survodutide (Dual GLP-1/Glucagon Agonist)

A dual agonist of GLP-1 and glucagon receptors being developed for obesity and MASH. Glucagon component provides added metabolic benefits through increased energy expenditure.

How Survodutide Works

Activates GLP-1 receptors to reduce appetite while glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and amino acid catabolism.

Dosing Protocol

• Typical dose: 0.6-6.0 mg
• Frequency: Once weekly
• Duration: Ongoing
• Route: Subcutaneous

Reported Benefits

• Significant weight loss (up to 19%)
• Liver fat reduction
• Increased energy expenditure
• MASH resolution potential
• Improved lipid profile

Potential Side Effects

• Nausea
• Diarrhea
• Vomiting
• Decreased appetite
• Constipation

Research Citations

1. Phase 2 survodutide for weight management (2023) - Survodutide 4.8mg achieved 18.7% body weight reduction at 46 weeks.
2. Survodutide in MASH: Phase 2b results (2024) - Up to 83% achieved MASH resolution with significant fibrosis improvement at 48 weeks.

Related Weight Management Compounds

• AOD-9604 - Full Profile
• Semaglutide - Full Profile
• Tirzepatide - Full Profile
• Retatrutide - Full Profile
• Tesofensine - Full Profile
• CagriSema - Full Profile

View full Survodutide profile with 3D molecule viewer →